Indeed, we reported that the above listed dopamine D3 receptor antagonists significantly reversed ABCG2-mediated MDR to antineoplastic drugs in lung (i.e., H460 and H460-MX20) and colon cancer cell lines (i.e., S1 and S1-M180) overexpressing ABCG2 transporters [19]. This evidence concerns the gene ABCG2 and malignant colon neoplasm.